Drug intelligence / Profile preview

Nazilai

Development stage: Unknown
Lead developer: Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences
Administration: Oral

Overview

Nazilai is a traditional Uyghur herbal medicine formulated as granules for the treatment of the common cold. Specifically targeting "heat-type" Nazilai (热性乃孜来) symptoms in Uyghur medical theory, the drug is being developed by the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences. It is currently undergoing Phase II clinical evaluation in China to assess its efficacy and safety in alleviating symptoms of upper respiratory tract infections in adults.

Other names: Nazilai granulesRexing Nazilai热性乃孜来

Beyond the preview

Go deeper on Nazilai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nazilai.

Explore the full profile